Doublet Shows Activity in Rare, Aggressive Kidney Cancer

(MedPage Today) -- Bevacizumab (Avastin) combined with erlotinib (Tarceva) showed activity in patients with hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated or sporadic papillary renal cell carcinoma (RCC), a phase II trial suggested...